Zelluna Immunotherapy is a Norwegian biopharma company with a global focus, developing T-cell receptor based immunotherapies for a broad range of solid cancers with high unmet need. The company core asset is a portfolio of non-engineered tumor specific T-cell receptors (TCR) isolated and sequenced from long term surviving patients from peptide based cancer vaccine trials. The TCR have been tailored by the human immune system to deliver an optimal combination of specificity and affinity for safe and efficient therapy, recognizing peptides in the context of high frequency HLA Class I and Class II alleles. Our technology has been developed in collaboration with the Department of Cell Therapy at the Oslo University Hospital through a cooperative research and development agreement (CRADA). Zelluna has a comprehensive clinical pipeline of engineered adoptive cell therapy products entering clinical translation.